Expert Lectures held on Depression in Patients with Comorbidity

Depression is the most frequent psychiatric disorder and the most important cause of work incapacity in the world. This was the discussion topic of Prof Dr Abdulah Kučukalić and D.Sc. Alma Džubur Kulenović at a prominent scientific conference held in Sarajevo on 16 April 2014.


Expert Lectures held on Depression in Patients with Comorbidity
Bosnalijek, in cooperation with the Medical Chamber of Sarajevo Canton and the Masters of Pharmacy Chamber of the Federation of Bosnia and Herzegovina, organised expert scientific lectures on two topics: 1) the proper selection of selective serotonin reuptake inhibitors - SSRI - in the treatment of depressive disorders with comorbidity and 2) specifics of SSRI profiles.

On this occasion, as a renowned manufacturer with an extensive generic product range, Bosnalijek presented a new medicine contributing to the improvement of health in patients with depression and depressive anxiety disorders.

Nedim Uzunović, acting Manager of Bosnalijek, said, “In line with global trends in pharmacy and medicine, this year we have focused our efforts on the development of medicines with effect on the central nervous system” adding “We are proud to contribute to the development of the latest pharmacotherapeutic trends, which we strive to follow and implement in the territory of Bosnia and Herzegovina”.

Depression is the most frequent psychiatric disorder and the most important cause of work incapacity in the world. It usually occurs between 25 and 40 years of age but frequently can occur earlier, even in childhood. It is believed that prior to 2025 depression will be the second most frequent disorder in men and the first in women.
April 17, 2014
Previous news
Bosnalijek winner of the Award for Business Leaders of Sustainable Devel ... Danish journalists were convinced of the top quality of Bosnalijek Cooperation Agreement Signed between Bosnalijek and Abdi Ibrahim – Bosna ... Bosnalijek breaks its own business records Record semi-annual performance of Bosnalijek in 2022 Bosnalijek Opens New Facility for Manufacturing Liquid and Semisolid Pha ... Two Bosnalijek Teams Won Valuable Prizes at Dolorex B2B Night Relay Race ... Professional Lecture for Doctors and Patients Held On the Occasion of th ... Bosnalijek signs cooperation agreement with Mylan, a global healthcare c ... Bosnalijek Appoints US Major General David L. Grange (Ret.) as the Board ...
decembar 04. 2024 |
SASE |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%